Opens in a new tab

Curio Bioscience v 10x Genomics (CoA, 17 April 2024)

Date17 April 2024
CourtCoA
DivisionLuxembourg (LU)
Type of actionAppeal RoP220.1
Registry referenceAPL_12116/2024 · ORD_18194/2024
PartiesCurio Bioscience Inc. v. 10x Genomics, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 17 April 2024 (UPC_CoA_101/2024), the Court of Appeal set aside the order of the President of the Court of First Instance of 26 February 2024 and determined English, the language of EP 2 697 391, as the language of the provisional measures proceedings brought in German by 10x Genomics against Curio Bioscience before the Düsseldorf Local Division. The order, which carries a headnote, sets out how fairness under Article 49(5) UPCA is to be assessed: the circumstances of the case and of the parties come first, in particular the defendant’s position, which is decisive where the interests are evenly balanced.

Question

Is a change of the language of proceedings to the language of the patent, requested by the defendant, justified on grounds of fairness?

Decision

Although review of the President’s discretion is limited, the order was set aside for misinterpreting fairness (paragraphs 18 to 20). Relevant factors include the language commonly used in the technical field and that of the main evidence. The representatives’ language skills and the judges’ nationality are in principle irrelevant (paragraphs 21 to 23, 26 and 27). Curio is clearly smaller than 10x, so there was no need to decide whether it is an SME (paragraphs 24 and 38). A claimant, who chooses the court and the timing of the action, must expect to proceed in the language of the patent (paragraphs 29 to 34). Both companies being American, and the technology and most of the evidence being in English, the defendant’s interest prevailed (paragraphs 37, 39 and 43). If the order on provisional measures is appealed, the parties must file uncertified English translations of their pleadings at their own cost (Rule 7.2 RoP).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 49(1), (2), (3), (5) and (6), 50, 52(1), 69 and 74(3)
Rules of Procedure
Rules 7.2, 14.2, 118.5, 150, 152.2, 225, 242.1 and 323
European Patent Convention
Art. 14(8)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Appeal RoP220.1
Outcome (Dhenne Avocats summary)
La cour d'appel infirme le refus du président du tribunal de première instance et fixe l'anglais comme langue de la procédure de mesures provisoires, l'équité commandant de privilégier la situation de la défenderesse.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 697 391
Method and product for localised or spatial detection of nucleic acid in a tissue sample
recorded proprietor: Spatial Transcriptomics AB
Mentioned in the analysis (role not qualified)
Also mentioned in 28 other decision(s): 10x Genomics v Curio Bioscience (CFI, ORD_598272/2023, 30 April 2024) · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_658/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_657/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, 5 August 2025) · 10x Genomics v Curio Bioscience (CFI, 4 August 2025) · 10x Genomics v Curio Bioscience (CFI, 16 June 2025) · 10x Genomics v Curio Bioscience (CFI, 4 June 2025) · 10x Genomics v Curio Bioscience (CFI, 2 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.